Novartis' Anti-Seizure Drug New Target Of PL Suit

Law360, New York (December 5, 2007, 12:00 AM EST) -- Already besieged by hundreds of product liability suits surrounding its contentious bone density drugs, Novartis Pharmaceuticals Corp. is now facing a fresh assault over anti-seizure medication Trileptal.

The lawsuit, believed to be one of the first of its kind, was removed to a Florida district court Monday. It claims Trileptal has life-threatening side effects that Novartis deliberately concealed from consumers.

Plaintiff Lori Feldman initially brought the suit in a Florida state court, alleging she suffered a serious adverse reaction and was diagnosed with the debilitating Stevens-Johnson...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.